Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin L Ebert

Showing results (241-250 of 339) with videos related to

Pageof 34
Sort By:
Blood|November 30, 2016
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelHartmut Döhner, Elihu Estey, David Grimwade, et al.
Cancer Cell|December 11, 2007
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate allelesStefan Fröhling, Claudia Scholl, Ross L Levine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2022
Clonal Hematopoiesis and Risk of Incident Lung CancerRuiyi Tian, Brian Wiley, Jie Liu, et al.
Blood|July 7, 2022
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELNHartmut Döhner, Andrew H Wei, Frederick R Appelbaum, et al.
Blood|May 3, 2019
Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogsAdam S Sperling, Michael Burgess, Hasmik Keshishian, et al.
Blood|May 8, 2009
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignanciesOmar Abdel-Wahab, Ann Mullally, Cyrus Hedvat, et al.
Blood Cancer Discovery|May 24, 2021
Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignanciesAline Renneville, Jessica A Gasser, Daniel E Grinshpun, et al.
Blood|August 12, 2024
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendationsHartmut Döhner, Courtney D DiNardo, Frederick R Appelbaum, et al.
JCI Insight|December 22, 2020
Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AMLZuzana Tothova, Anne-Laure Valton, Rebecca A Gorelov, et al.
Blood|July 31, 2020
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotypeDavid A Sallman, Amy F McLemore, Amy L Aldrich, et al.
Pageof 34

Showing results (241-250 of 339) with videos related to

Sort By:
Pageof 34
Blood|November 30, 2016
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelHartmut Döhner, Elihu Estey, David Grimwade, et al.
Cancer Cell|December 11, 2007
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate allelesStefan Fröhling, Claudia Scholl, Ross L Levine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2022
Clonal Hematopoiesis and Risk of Incident Lung CancerRuiyi Tian, Brian Wiley, Jie Liu, et al.
Blood|July 7, 2022
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELNHartmut Döhner, Andrew H Wei, Frederick R Appelbaum, et al.
Blood|May 3, 2019
Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogsAdam S Sperling, Michael Burgess, Hasmik Keshishian, et al.
Blood|May 8, 2009
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignanciesOmar Abdel-Wahab, Ann Mullally, Cyrus Hedvat, et al.
Blood Cancer Discovery|May 24, 2021
Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignanciesAline Renneville, Jessica A Gasser, Daniel E Grinshpun, et al.
Blood|August 12, 2024
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendationsHartmut Döhner, Courtney D DiNardo, Frederick R Appelbaum, et al.
JCI Insight|December 22, 2020
Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AMLZuzana Tothova, Anne-Laure Valton, Rebecca A Gorelov, et al.
Blood|July 31, 2020
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotypeDavid A Sallman, Amy F McLemore, Amy L Aldrich, et al.
Pageof 34